Here's Why You Should Add URGN Stock to Your Portfolio Now
UroGen Pharma (URGN) is presented as a strong buy opportunity due to its transition into a commercial-stage biotech company with two marketed products, Zusduri and Jelmyto. The article highlights Zusduri's significant revenue growth and potential as a blockbuster drug, alongside Jelmyto's stable revenue base and UGN-103's potential to expand UroGen's bladder cancer market. The company also has other pipeline assets and a strong Zacks Rank, making it an attractive investment.
UR8 Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for UroGen Pharma Ltd. (UR8) stock, based on analyst opinions. It details the company's financials, including past earnings and revenue, future earnings expectations, and key metrics like EBITDA. The report also confirms that UroGen Pharma Ltd. does not pay dividends and outlines its employee count.
UroGen Pharma (URGN) Stock Looks About Right As Sales Catch Up
UroGen Pharma's stock has seen a significant rally, prompting an analysis of its current valuation against sales. The company trades at a P/S ratio of 10.8x, which is below the biotech industry average but above its peer group. While its share price reflects commercial progress, investors are now weighing future execution against this valuation.
UroGen Pharma Ltd. (URGN) stock price, news, quote and history
This page provides a comprehensive overview of UroGen Pharma Ltd. (URGN) stock, including its current price, historical data, key statistics, and financial highlights. It details the company's biotechnology focus on urothelial and specialty cancers, its product offerings like RTGel and Jelmyto, and its pipeline of clinical-stage candidates. The article also includes analyst insights, earnings trends, and performance metrics compared to the S&P 500.
Is UroGen’s (URGN) Commercial Engine Strong Enough To Fund Its Pipeline Ambitions?
UroGen Pharma (URGN) is an oncology and urology therapeutics company focused on localized drug delivery systems. The company recently announced an agreement with IntraGel Therapeutics for new oncology products and an investment in their equity, leveraging its strong commercial performance from ZUSDURI, which saw significant revenue growth in Q2 2026. While UroGen shows pipeline expansion and strong commercial results, the market remains somewhat skeptical, as indicated by short interest and a high forward earnings multiple, reflecting a divided view on its growth prospects.
UroGen Pharma general counsel sells $64,618 in shares
Jason Drew Smith, General Counsel at UroGen Pharma Ltd. (NASDAQ:URGN), recently sold 1,519 ordinary shares for $64,618 to cover tax obligations from vested restricted stock units. This transaction followed his acquisition of 3,334 shares through restricted stock unit settlement. The company has shown strong performance, with shares up 112% over the past year, and recently reported impressive Q2 2026 revenues driven by its bladder-cancer drug ZUSDURI.
UroGen Pharma (URGN) GC exercises RSUs, then sells shares for tax withholding
UroGen Pharma's General Counsel, Jason Drew Smith, exercised 3,334 Restricted Stock Units on September 7, 2026, receiving an equal number of ordinary shares. The following day, he sold 1,519 of these shares at $42.54 each to cover tax withholding obligations. This transaction relates to an RSU grant from September 2023, which is scheduled to vest in three annual installments.
UroGen Pharma's General Counsel Reports RSU Vesting and Tax-Related Share Sale
Jason Drew Smith, General Counsel of UroGen Pharma Ltd. (NASDAQ: URGN), reported the vesting of 3,334 restricted stock units (RSUs) on September 7, 2026. Following this, he sold 1,519 ordinary shares at $42.54 each on September 8, 2026, to cover tax liabilities. Smith now directly owns 53,141 ordinary shares after these transactions.
UroGen Pharma CMO Mark Schoenberg sells $37,383 in shares
Mark Schoenberg, CMO of UroGen Pharma, sold 871 ordinary shares valued at $37,383 to cover tax obligations from restricted stock unit settlements. This transaction occurred on September 8, 2026, a day after he acquired 1,667 shares through RSU settlements. UroGen Pharma has recently reported strong Q2 2026 financial results, with revenue surpassing forecasts, driven by ZUSDURI sales, and its stock shows significant one-year returns.
Urogen Pharma: Upside After Bladder Cancer Launch (NASDAQ:URGN)
UroGen Pharma has transitioned into a commercial-stage biopharma with the strong adoption of Zusduri for recurrent non-muscle-invasive bladder cancer, achieving an 80% complete response rate in the ENVISION trial. The company is also progressing with URGN-103, a next-generation product, which has completed NDA submission. Despite a short cash runway and execution risks, the article maintains a "Buy" rating on URGN stock due to robust early commercial execution and significant market potential.
UroGen Pharma (NASDAQ: URGN) officer plans 10,000-share sale after RSUs vest
UroGen Pharma (URGN) officer Jason Smith plans to sell 10,000 ordinary shares after RSUs vested on September 8, 2026. The sale, detailed in a Rule 144 SEC filing, is partly to cover tax withholding obligations. Oppenheimer & Co. Inc. is listed as the broker for the transaction.
UroGen Pharma (URGN) officer lines up 5,000-share sale from RSUs
UroGen Pharma officer Mark Schoenberg has filed a Form 144 notice to sell up to 5,000 ordinary shares obtained from the vesting of restricted stock units (RSUs) on September 8, 2026. This planned sale follows a previous sale of 5,222 shares on June 8, 2026, which were sold to cover tax withholding obligations. The current transaction involves no cash consideration for the RSU-vested shares and will be handled by Oppenheimer & Co. Inc.
UroGen Pharma (NASDAQ:URGN) Combines High Growth Momentum with a Breakout Setup
UroGen Pharma (NASDAQ:URGN) is highlighted as an attractive growth stock due to its accelerating revenue, particularly strong sales growth, and narrowing losses as it transitions to commercialization. The stock also presents a favorable technical setup with a high technical rating and consolidation, suggesting a potential breakout. While not yet profitable and exhibiting some short-term volatility, the combination of strong fundamentals and a constructive technical pattern makes it an interesting candidate for growth-oriented investors.
Trading the Move, Not the Narrative: (URGN) Edition
This article provides an AI-generated analysis of Urogen Pharma Ltd. (NASDAQ: URGN), highlighting weak near and mid-term sentiment despite a long-term positive outlook. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss points. The analysis emphasizes an exceptional risk-reward short setup and provides multi-timeframe signal analysis for different investment horizons.
Trade Alert: Chief Medical Officer Of UroGen Pharma Mark Schoenberg Has Sold Stock
Mark Schoenberg, the Chief Medical Officer of UroGen Pharma, has recently sold shares in the company. This trade alert indicates a transaction involving a key insider at UroGen Pharma.
UroGen Pharma (URGN) Faces A Valuation Test Following Its FDA Filing
UroGen Pharma (URGN) recently submitted a New Drug Application to the FDA for UGN-103, following strong share price performance. While a narrative valuation suggests the stock is overvalued at $46.86 compared to a fair value of $36.11, another view using the P/S ratio indicates it's more balanced, being below the US Biotechs average. The article advises investors to review the full picture, considering both potential rewards and warning signs.
UroGen Pharma (URGN) Faces A Valuation Test Following Its FDA Filing
UroGen Pharma (URGN) recently submitted a New Drug Application to the FDA for UGN-103, backed by strong Phase 3 trial data, which has led to significant share price appreciation. Despite this momentum and a positive outlook for their minimally invasive therapies, Simply Wall St's analysis suggests the stock might be overvalued at its current price of $46.86 compared to a fair value of $36.11, though other metrics like P/S ratio present a more balanced picture. The company's future performance hinges on successful product uptake and avoiding trial setbacks, given its reliance on a narrow product set and current operating losses.
UGN-103 NDA Filing for Recurrent Bladder Cancer Might Change The Case For Investing In UroGen Pharma (URGN)
UroGen Pharma has submitted a New Drug Application (NDA) to the FDA for UGN-103, a mitomycin solution for recurrent low-grade non-muscle invasive bladder cancer, supported by positive Phase 3 data. This filing is a key catalyst for the company, aiming to expand its RTGel-based bladder cancer franchise beyond ZUSDURI and address prior reimbursement issues. While analysts have varying projections for UroGen's future revenue and earnings, the success of UGN-103 is crucial for its investment narrative, given ongoing losses and a limited cash runway.
H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $75
H.C. Wainwright has reiterated its Buy rating for UroGen Pharma Ltd (URGN.US) and maintained its target price at $75. This continued positive outlook from the analyst firm suggests confidence in the company's future performance.
UGN-103 NDA Filing for Recurrent Bladder Cancer Might Change The Case For Investing In UroGen Pharma (URGN)
UroGen Pharma (URGN) has submitted a New Drug Application (NDA) to the FDA for UGN-103, a treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. This filing, supported by positive Phase 3 data, could significantly reshape UroGen Pharma's investment narrative by expanding its RTGel-based bladder cancer franchise beyond ZUSDURI. However, investors should be aware of the company's ongoing losses and limited cash runway, which pose risks if revenue growth or new approvals fall short.
UroGen (NASDAQ: URGN) officer sold $750K in stock, plans more
An officer at UroGen Pharma Ltd. (NASDAQ: URGN), Mark Schoenberg, plans to sell additional common shares through RBC Capital Markets LLC. This follows previous sales in June and July 2026, totaling 20,000 shares for $750,151, which were acquired via a stock option exercise in January 2023. The filing indicates a neutral impact and sentiment regarding these planned sales.
M&A Roundup: IntraGel & UroGen Sign Collaboration & Investment Agreements, Lupin & Tenpoint Form Commercialization Collaboration
This M&A roundup highlights two key biopharma agreements. UroGen Pharma has invested up to $7 million in IntraGel Therapeutics, securing an exclusive option to license Tumocure for advanced head and neck cancer and access to IntraGel's SRGel platform. Separately, Lupin Limited's subsidiary, VISUfarma B.V., has entered into an exclusive licensing agreement with Tenpoint Therapeutics to commercialize Yuvezzi, an ophthalmic product for presbyopia, across Europe.
INTRAGEL THERAPEUTICS LTD announced that it expects to receive $7 million in funding from UroGen Pharma Ltd.
INTRAGEL THERAPEUTICS LTD announced that it expects to receive $7 million in funding from UroGen Pharma Ltd. The funding involves UroGen Pharma participating in an investment agreement to purchase convertible preferred stock from IntraGel. This development follows UroGen Pharma's recent submission of a New Drug Application to the FDA for UGN-103 in recurrent bladder cancer and several analyst rating adjustments.
UroGen Pharma secures option to license IntraGel SRGel program, agrees up to $7M investment
UroGen Pharma has entered into an agreement with IntraGel, securing an exclusive option to license IntraGel’s SRGel-based TumoCure program for head and neck cancer. This agreement also includes options for additional worldwide licenses to combine SRGel with other compounds, expanding UroGen's potential pipeline. Additionally, UroGen will invest up to $7 million in IntraGel equity to support this collaboration.
UroGen Pharma secures option deal with IntraGel for cancer tech
UroGen Pharma has entered into a strategic option and research license agreement with IntraGel Therapeutics, including an equity investment of up to $7 million. This deal grants UroGen exclusive options to develop up to three oncology products utilizing IntraGel's SRGel platform, a biodegradable sustained-release drug delivery technology. The agreement also includes an exclusive option for TumoCure, an investigational therapy for advanced head and neck cancer, following its Phase 2 clinical study completion.
UroGen Announces Strategic Collaboration and Investment
UroGen Pharma Ltd. has entered into a strategic Option and Research License Agreement and an Investment Agreement with IntraGel Therapeutics, Ltd. This collaboration grants UroGen access to IntraGel's proprietary SRGel platform for developing oncology products and an exclusive option to license TumoCure, an investigational therapy for advanced head and neck cancer. UroGen will also invest up to $7 million in IntraGel.
IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies
IntraGel Therapeutics and UroGen Pharma have announced strategic collaboration and investment agreements focused on advancing sustained-release investigational oncology therapies. UroGen will invest up to $7 million in IntraGel, supporting the Phase 2 clinical development of TumoCure for head and neck cancer. Additionally, UroGen gains access to IntraGel's proprietary SRGel™ platform for localized drug delivery and an exclusive option to acquire worldwide rights to TumoCure and potentially develop up to three more oncology products using the SRGel platform.
UroGen Announces Strategic Collaboration and Investment
UroGen Pharma Ltd. announced a strategic Option and Research License Agreement and an Investment Agreement with IntraGel Therapeutics, Ltd. This collaboration grants UroGen access to IntraGel's proprietary SRGel platform for developing up to three oncology products and an exclusive option to acquire worldwide rights to TumoCure, an investigational therapy for advanced head and neck cancer. UroGen will also invest up to $7 million in IntraGel.
IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies
IntraGel Therapeutics and UroGen Pharma have signed strategic collaboration and investment agreements to advance sustained-release investigational oncology therapies. UroGen will invest up to $7 million in IntraGel, supporting the Phase 2 clinical study of TumoCure for head and neck cancer, and gains access to IntraGel's proprietary SRGel™ platform for localized drug delivery in solid tumors. This collaboration aims to expand UroGen's oncology pipeline and accelerate the development of TumoCure and other SRGel-based products.
Urogen Pharma stock hits 52-week high at 49.69 USD
Urogen Pharma (URGN) stock has reached a new 52-week high of $49.69, currently trading slightly below this peak at $49.81. This surge reflects an impressive 158.56% increase over the past year and 109% year-to-date returns, driven by strong revenue growth and significant gross profit margins. The company's recent Q2 2026 revenue of $72.5 million, boosted by its bladder-cancer drug ZUSDURI, surpassed analyst forecasts, leading Guggenheim to raise its price target to $58.
Rice Hall James & Associates LLC Purchases Shares of 300,650 Urogen Pharma $URGN
Rice Hall James & Associates LLC has acquired a new stake of 300,650 shares in Urogen Pharma (NASDAQ:URGN), valued at approximately $11.1 million, representing about 0.62% of the company. Despite Urogen Pharma reporting quarterly revenue above expectations, it missed earnings per share estimates, and insiders sold over 25,000 shares recently. The stock currently holds a "Moderate Buy" consensus from analysts with an average target price of $50.38.
UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC
UroGen Pharma Ltd. has submitted a New Drug Application (NDA) to the U.S. FDA for UGN-103, an investigational treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The submission is supported by Phase 3 UTOPIA trial data, which showed a 77.8% three-month complete response rate and a 94.5% six-month duration of response. UGN-103 leverages UroGen's RTGel technology, aiming for improved manufacturing, reconstitution, and extended shelf-life compared to its predecessor, ZUSDURI.
Ninety-nine patients entered a bladder cancer trial—what came next?
UroGen Pharma has submitted a New Drug Application (NDA) to the FDA for UGN-103, an investigational treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The submission is supported by data from the Phase 3 UTOPIA trial, which showed a 77.8% three-month complete response rate and a 94.5% six-month duration of response. UGN-103 leverages UroGen's RTGel sustained-release technology, building upon the foundation of their FDA-approved drug ZUSDURI, with intellectual property coverage expected until July 2044.
Is UroGen Pharma (URGN) Overvalued As Sales Growth And Patent Clarity Lift Confidence?
UroGen Pharma (URGN) is experiencing increased investor confidence following strong Q2 2026 earnings, which showed higher sales and a smaller net loss, alongside positive updates on ZUSDURI adoption and JELMYTO patent litigation. Despite a significant share price surge, there's a debate regarding its valuation; one narrative suggests it's 33.3% overvalued at $48.12 compared to a $36.11 fair value, while Simply Wall St's DCF model indicates a much higher fair value of $358.39. The company's shift towards minimally invasive therapies and long-term durability data for ZUSDURI contribute to its improved market perception, though risks like ongoing losses and concentrated revenue exposure remain.
California State Teachers Retirement System Grows Stock Holdings in Urogen Pharma $URGN
The California State Teachers Retirement System significantly increased its holdings in Urogen Pharma (NASDAQ:URGN) by 1,605.5% in the first quarter, now owning 38,750 shares valued at $697,000. Institutional investors collectively hold 91.29% of the company, which has an average analyst rating of "Moderate Buy" and a consensus price target of $48.78. Despite reporting higher-than-expected revenue of $72.46 million, Urogen Pharma posted a loss of $0.28 per share, slightly missing analyst estimates.
Is UroGen Pharma (URGN) Overvalued As Sales Growth And Patent Clarity Lift Confidence?
UroGen Pharma (URGN) is experiencing increased attention following strong Q2 2026 earnings, which showed higher sales and progress on product adoption and patent litigation. Despite a significant share price increase of over 100% year-to-date, there's a valuation debate, with a popular narrative suggesting the stock is 33.3% overvalued at $48.12 compared to a $36.11 fair value, while Simply Wall St's DCF model indicates a much higher future cash flow value of $358.39. The article advises investors to review both upside potential and risks, including ongoing losses and concentrated revenue.
Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice
Urogen Pharma (URGN) is highlighted as a strong momentum pick due to its "A" Momentum Style Score from Zacks and a Zacks Rank of #2 (Buy). The article details URGN's impressive short-term and long-term price performance, outperforming both its industry and the S&P 500. Additionally, positive earnings estimate revisions further support its potential for near-term growth.
(URGN) Volatility Zones as Tactical Triggers
This article from Stock Traders Daily discusses Urogen Pharma Ltd. (NASDAQ: URGN) and presents AI-generated trading strategies based on volatility zones. It highlights strong sentiment across all time horizons supporting an overweight bias, notes the absence of resistance levels above the current price, and provides specific entry, target, and stop-loss levels for long, breakout, and short strategies.
UroGen Pharma (URGN): TD Bank group discloses 3.37M shares, 6.9% beneficial stake
The Toronto-Dominion Bank and TD Securities Inc. have jointly reported beneficial ownership of 3,371,263 ordinary shares of UroGen Pharma Ltd. This represents a 6.9% stake in the company. The filing specifies the individual voting and dispositive powers of both TD Bank and TD Securities over these shares, clarifying that TD Bank disclaims beneficial ownership of TD Securities' shares except for its pecuniary interest.
UroGen (URGN) Q2 2026 Earnings Call Transcript
UroGen Pharma (URGN) reported strong Q2 2026 results driven by the ZUSDURI launch, with total revenue reaching $72.5 million. ZUSDURI's commercial demand is expanding into community urology practices, showing increased repeat utilization and physician confidence. The company is advancing its pipeline with NDA submissions for UGN-103 and progression of UGN-501, and remains on track for profitability using existing capital despite increased marketing and development investments.
Urogen Pharma (NASDAQ:URGN) Hits New 1-Year High - Time to Buy?
Urogen Pharma (NASDAQ:URGN) recently reached a new 52-week high of $48.21, reflecting generally positive analyst sentiment with a "Moderate Buy" consensus rating and price targets up to $75. Despite exceeding revenue expectations with $72.46 million, the company missed EPS estimates, reporting a loss of $0.28 per share. Insider selling and substantial institutional ownership (91.29%) characterize recent trading activity.
UroGen Pharma (URGN) Is Up 21.7% After Q2 Revenue Triples And Loss Narrows Has The Bull Case Changed?
UroGen Pharma (URGN) reported strong Q2 2026 results with sales tripling to US$72.46 million and net loss narrowing to US$14.35 million. This performance, along with expanded loan facilities, supports the company's investment narrative of scaling its urology-focused drugs, though it remains unprofitable. Analysts project significant revenue growth by 2029, but investors are cautioned about continued operating losses and negative equity.
URGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that UroGen Pharma Ltd. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against UroGen Pharma Ltd. (NASDAQ:URGN) on behalf of investors who purchased securities between July 27, 2023, and May 15, 2025. The lawsuit alleges that UroGen made misleading statements and failed to disclose critical information regarding the design and prospects of its ENVISION clinical study for UGN-102, which posed a substantial risk to FDA approval. Investors with losses have until July 28, 2025, to seek appointment as lead plaintiff.
UroGen Pharma (URGN) Is Up 21.7% After Q2 Revenue Triples And Loss Narrows Has The Bull Case Changed?
UroGen Pharma (URGN) reported significantly improved Q2 2026 results, with revenue tripling to US$72.46 million and net loss narrowing to US$14.35 million. These results indicate emerging operating leverage, supported by an expanded loan facility, which provides financial flexibility despite the company remaining unprofitable. While the strong performance supports the investment narrative, UroGen Pharma's reliance on capital access and sustained commercial execution due to continued operating losses and negative equity remains a key risk.
UroGen Pharma (URGN) Is Up 21.7% After Q2 Revenue Triples And Loss Narrows Has The Bull Case Changed?
UroGen Pharma (URGN) saw its stock rise by 21.7% after reporting significant improvements in its Q2 2026 results, with revenue tripling to US$72.46 million and net loss narrowing. The company's first-half sales nearly tripled, and its net loss was halved, suggesting emerging operating leverage. While these results and an expanded loan facility provide financial flexibility and support the company's growth narrative, UroGen Pharma remains unprofitable with negative equity, highlighting its dependence on continued commercial execution and capital access.
UroGen Pharma (URGN) Stock Looks Fairly Priced Despite Its 210% Run
UroGen Pharma (URGN) has seen a significant 210% return over the last five years, but its current valuation suggests the stock is now fairly priced rather than undervalued. The company's P/S ratio is aligned with its modelled fair P/S, indicating no clear discount or premium. While future revenue growth and pipeline conversion could support the valuation, ongoing funding needs and execution risks limit further upside.
Q3 EPS Estimates for Urogen Pharma Lifted by HC Wainwright
HC Wainwright has raised its Q3 2026 EPS estimate for Urogen Pharma to a loss of $0.07 per share from a previous loss of $0.37, while maintaining a "Buy" rating and a $75 price target. This positive adjustment comes as Urogen Pharma’s Q2 revenue of $72.46 million exceeded analyst forecasts, despite a slight miss on EPS. The company currently holds a "Moderate Buy" consensus rating with an average price target of $48.78.
UroGen Pharma Ltd. Revenue Breakdown – MUN:UR8
UroGen Pharma Ltd. (MUN:UR8) generated €93.49 million in revenue last year, primarily from its RTGel Reverse Thermal Hydrogel segment, which accounted for €93.48 million. The majority of this revenue, €93.48 million, originated from Israel and the United States. This represents an increase from the previous year's segment revenue of €87.32 million.
Why UroGen Pharma (URGN) Is Up 22.8% After Q2 2026 Revenue Nearly Tripled And Losses Narrowed
UroGen Pharma (URGN) saw its stock rise 22.8% after reporting a nearly tripling of Q2 2026 revenue to US$72.46 million and a significant narrowing of its net loss to US$14.35 million. While the company's improved operating leverage supports its growth thesis, concerns remain regarding its cash runway and dependence on external funding, despite an expanded loan facility. Analysts project substantial revenue growth and a move to profitability by 2029, though fair value estimates suggest a potential downside from its current price.
UroGen Pharma (URGN) Earnings Put Its Fair Value Debate Back In Focus
UroGen Pharma (URGN) reported strong Q2 2026 results, with increased sales and a reduced net loss, leading to significant stock price appreciation. This has sparked debate over its fair value, with one narrative suggesting it's 30% overvalued at $36.11, while another Discounted Cash Flow model indicates it is significantly undervalued at $355.54 per share. Investors are now evaluating whether the recent gains fully reflect its potential or if further upside exists.
